Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stage II and stage III colon cancer: treatment advances and future directions.
Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, André T, de Gramont A; GERCOR (French Oncology Research Group). Rousseau B, et al. Among authors: louvet c. Cancer J. 2010 May-Jun;16(3):202-9. doi: 10.1097/PPO.0b013e3181ddc5bf. Cancer J. 2010. PMID: 20526097 Review.
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR. Soularue É, et al. Among authors: louvet c. Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3. Bull Cancer. 2015. PMID: 25744576
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A. Tournigand C, et al. Among authors: louvet c. Lancet Oncol. 2015 Nov;16(15):1493-1505. doi: 10.1016/S1470-2045(15)00216-8. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26474518 Clinical Trial.
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).
Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F. Vernerey D, et al. Among authors: louvet c. Br J Cancer. 2016 Jul 26;115(3):281-9. doi: 10.1038/bjc.2016.212. Epub 2016 Jul 12. Br J Cancer. 2016. PMID: 27404456 Free PMC article. Clinical Trial.
[Are cancer outpatients ready for e-medicine?].
Kempf E, Prévost A, Rousseau B, Macquin-Mavier I, Louvet C, Tournigand C. Kempf E, et al. Among authors: louvet c. Bull Cancer. 2016 Oct;103(10):841-848. doi: 10.1016/j.bulcan.2016.06.004. Epub 2016 Aug 3. Bull Cancer. 2016. PMID: 27497498 French.
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D. Vienot A, et al. Among authors: louvet c. J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx037. J Natl Cancer Inst. 2017. PMID: 28383673
[Clinical research activity of the French cancer cooperative network: Overview and perspectives].
Dubois C, Morin F, Moro-Sibilot D, Langlais A, Seitz JF, Girault C, Salles G, Haioun C, Deschaseaux P, Casassus P, Mathiot C, Pujade-Lauraine É, Votan B, Louvet C, Delpeut C, Bardet É, Vintonenko N, Hoang Xuan K, Vo M, Michon J, Milleron B. Dubois C, et al. Among authors: louvet c. Bull Cancer. 2017 Jul-Aug;104(7-8):652-661. doi: 10.1016/j.bulcan.2017.05.006. Epub 2017 Jul 5. Bull Cancer. 2017. PMID: 28688747 French.
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER. André T, et al. Among authors: louvet c. J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5. J Clin Oncol. 2018. PMID: 29620995 Clinical Trial.
305 results